AGIOS PHARMACEUTICALS, INC. 8-K

What Happened
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) filed a Current Report on Form 8-K on January 12, 2026 (Item 7.01, Regulation FD Disclosure) to announce a press release outlining its anticipated 2026 milestones. The company said it will discuss those milestones at its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The press release and the presentation slides were furnished as Exhibits 99.1 and 99.2 to the 8-K and are incorporated by reference. The filing was signed by CEO Brian Goff.

Key Details

• Filing date: January 12, 2026 (Form 8-K, Item 7.01 – Regulation FD Disclosure).
• Conference presentation: 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
• Materials furnished: Press release (Exhibit 99.1) and presentation slides (Exhibit 99.2).
• Signature: Report signed by Brian Goff, Chief Executive Officer.

Why It Matters
This 8-K provides forward-looking operational milestones and investor-facing materials that may outline upcoming clinical, regulatory, or business catalysts for 2026. Because the disclosure was made under Regulation FD and exhibits were furnished, all investors receive the information publicly and simultaneously. The filing does not include quarterly earnings, financial statements, or executive changes — it is focused on milestone guidance and the company’s JPMorgan presentation. Investors should review the released press release and slides for specifics on timelines and program priorities.